41.79
1.83%
+0.75
Pre-market:
41.85
0.06
+0.14%
Celldex Therapeutics Inc. stock is currently priced at $41.79, with a 24-hour trading volume of 490.05K.
It has seen a +1.83% increased in the last 24 hours and a -18.12% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $41.12 pivot point. If it approaches the $41.83 resistance level, significant changes may occur.
Celldex Therapeutics Inc. Stock (CLDX) Financials Data
Celldex Therapeutics Inc. (CLDX) Revenue 2023
CLDX reported a revenue (TTM) of $6.88 million for the quarter ending December 31, 2023, a +192.02% rise year-over-year.
Celldex Therapeutics Inc. (CLDX) Net Income 2023
CLDX net income (TTM) was -$141.43 million for the quarter ending December 31, 2023, a -25.91% decrease year-over-year.
Celldex Therapeutics Inc. (CLDX) Cash Flow 2023
CLDX recorded a free cash flow (TTM) of -$109.11 million for the quarter ending December 31, 2023, a -3.36% decrease year-over-year.
Celldex Therapeutics Inc. (CLDX) Earnings per Share 2023
CLDX earnings per share (TTM) was -$2.92 for the quarter ending December 31, 2023, a -22.18% decline year-over-year.
Celldex Therapeutics Inc. Stock (CLDX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Feb 13 '24 |
Option Exercise |
3.86 |
24,166 |
93,163 |
25,924 |
Martin Samuel Bates | SVP AND CFO |
Jan 02 '24 |
Option Exercise |
2.78 |
10,750 |
29,885 |
35,128 |
Celldex Therapeutics Inc. Stock (CLDX) Latest News
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
Zacks Investment Research
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
GlobeNewswire Inc.
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
GlobeNewswire Inc.
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Benzinga
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
GlobeNewswire Inc.
About Celldex Therapeutics Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Cap:
|
Volume (24h):